CPSE:GMABBiotechs
How Investors Are Reacting To Genmab (CPSE:GMAB) Refocusing On Late-Stage Antibodies After Axing Acasunlimab
Genmab A/S recently reaffirmed its 2025 earnings guidance and decided to discontinue further clinical development of acasunlimab after evaluating its portfolio and the evolving competitive landscape.
By reallocating resources toward late-stage assets such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan (Rina-S), Genmab is sharpening its late-stage antibody pipeline focus.
We will now examine how concentrating capital on EPKINLY, petosemtamab and Rina-S could reshape Genmab’s...